Cargando…
Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling
BACKGROUND: Lovastatin, an HMG-CoA inhibitor and an effective cholesterol lowering drug, exhibits anti-neoplastic activity towards several types of cancer, although the underlying mechanism is still not fully understood. Herein, we investigated mechanism of growth inhibition of leukemic cells by lov...
Autores principales: | Gao, Jian, Hu, Jifen, Yu, Fang, Wang, Chunlin, Sheng, Danmei, Liu, Wuling, Hu, Anling, Yu, Kunling, Xiao, Xiao, Kuang, Yi, Zacksenhaus, Eldad, Gajendran, Babu, Ben-David, Yaacov |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071686/ https://www.ncbi.nlm.nih.gov/pubmed/37016335 http://dx.doi.org/10.1186/s12885-023-10742-4 |
Ejemplares similares
-
ERK activation via A1542/3 limonoids attenuates erythroleukemia through transcriptional stimulation of cholesterol biosynthesis genes
por: Yu, Fang, et al.
Publicado: (2021) -
FLI1 Regulates Histamine Decarboxylase Expression to Control Inflammation Signaling and Leukemia Progression
por: Hu, Jifen, et al.
Publicado: (2023) -
FLI1 Induces Megakaryopoiesis Gene Expression Through WAS/WIP-Dependent and Independent Mechanisms; Implications for Wiskott-Aldrich Syndrome
por: Wang, Chunlin, et al.
Publicado: (2021) -
UM171 cooperates with PIM1 inhibitors to restrict HSC expansion markers and suppress leukemia progression
por: Hu, Anling, et al.
Publicado: (2022) -
Selective ERK1/2 agonists isolated from Melia azedarach with potent anti-leukemic activity
por: Wang, Ning, et al.
Publicado: (2019)